title: Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.
abstract: OBJECTIVE
  First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab.
  
  
  METHODS
  This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months.
  
  
  RESULTS
  Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies.
  
  
  CONCLUSIONS
  Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.
authors.affiliation: Medical Oncology Unit--Department of Translational Oncology, Hospital Universitario La Paz-IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain. javier.decastro@salud.madrid.org.
authors.forename: J
authors.initials: J
authors.lastname: De Castro
authors.affiliation: Hospital Clínico Universitario San Carlos, Madrid, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: González-Larriba
authors.affiliation: Hospital Universitario Lucus Augusti, Lugo, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Vázquez
authors.affiliation: Hospital General Universitario de Alicante, Alicante, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Massutí
authors.affiliation: MD Anderson Cancer Center Madrid, Madrid, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Sanchez-Torres
authors.affiliation: Fundación Jiménez Díaz, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Dómine
authors.affiliation: Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Garrido
authors.affiliation: Centro Integral Oncológico Clara Campal, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Calles
authors.affiliation: Hospital Universitario Miguel Servet, Saragossa, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Artal
authors.affiliation: Hospital San Pedro de Alcántara, Cáceres, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Collado
authors.affiliation: Hospital Universitario Gregorio Marañón, Madrid, Spain.
authors.forename: R
authors.initials: R
authors.lastname: García
authors.affiliation: Hospital Infanta Sofía, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Sereno
authors.affiliation: Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Majem
authors.affiliation: Hospital General Universitario Morales Meseguer, Murcia, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Macías
authors.affiliation: Hospital Arnau Vilanova, Valencia, Spain.
authors.forename: O
authors.initials: O
authors.lastname: Juan
authors.affiliation: Hospital La Fe, Valencia, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Gómez-Codina
authors.affiliation: Complejo Hospitalario de Navarra--Hospital de Navarra, Pamplona, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Hernández
authors.affiliation: Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Lázaro
authors.affiliation: Complejo Hospitalario de Jaén, Jaén, Spain.
authors.forename: A L
authors.initials: AL
authors.lastname: Ortega
authors.affiliation: Hospital Regional Universitario Carlos Haya, Málaga, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Cobo
authors.affiliation: Hospital Universitario Virgen de la Victoria, Málaga, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Trigo
authors.affiliation: Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Carcereny
authors.affiliation: University Hospital of Antwerp, Antwerp, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Rolfo
authors.affiliation: Hospital General Universitario de Elda, Alicante, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Macia
authors.affiliation: Hospital Universitario Doctor Peset, Valencia, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Muñoz
authors.affiliation: Complejo Asistencial Universitario de León, León, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Diz
authors.affiliation: Hospital Universitario de Móstoles, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Méndez
authors.affiliation: Complejo Hospitalario Torrecárdenas, Almería, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Rosillo
authors.affiliation: Hospital Universitario Virgen del Rocío, Seville, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Paz-Ares
authors.affiliation: Roche Farma, S.A., Madrid, Spain.
authors.forename: J V
authors.initials: JV
authors.lastname: Cardona
authors.affiliation: Hospital Clínico Universitario Lozano Blesa, Saragossa, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Isla
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D018287:Carcinoma, Large Cell / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D017741:Survivors
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Bevacizumab; Bevacizumab maintenance therapy; First-line treatment; Non-squamous NSCLC; Observational study; Routine clinical practice setting